ISSUE 1422
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib (Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib (Mekinist – GSK) for melanomas with either BRAF V600E or V600K mutations. Dabrafenib is not recommended for patients with wild-type BRAF (BRAF-negative) melanoma, and trametinib is not recommended for patients who have received prior BRAF-inhibitor therapy.
STANDARD TREATMENT — BRAF V600E mutations are found in about 30-60% and BRAF V600K mutations are in about 10% of metastatic melanomas. First-line therapy for BRAF V600E mutant unresectable or metastatic melanoma is vemurafenib (Zelboraf), the first BRAF inhibitor approved by the FDA.1 For BRAF wild-type unresectable or metastatic melanoma, first-line therapy includes ipilimumab (Yervoy), an injectable
... more1. Vemurafenib (Zelboraf) for metastatic melanoma. Med Lett Drugs Ther 2011; 53:77.
2. Ipilimumab (Yervoy) for metastatic melanoma. Med Lett Drugs Ther 2011; 53:51.
7. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
8. Wholesale acquisition cost. Source: $ource® Monthly (Selected from FDB MedKnowledge™) July 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1422b
Electronic, downloadable article - $45